Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study
The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer.
Source: OncLive